DOCSLIB.ORG

Case Report Paroxysmal Nocturnal Hemoglobinuria with Rise of Blast Cells in Bone Marrow: a Case Report and Review of the Literature

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Case Report Paroxysmal Nocturnal Hemoglobinuria with Rise of Blast Cells in Bone Marrow: a Case Report and Review of the Literature Int J Clin Exp Med 2016;9(6):9625-9627 www.ijcem.com /ISSN:1940-5901/IJCEM0019479 Case Report Paroxysmal nocturnal hemoglobinuria with rise of blast cells in bone marrow: a case report and review of the literature Zhenglei Shen1, Liefen Yin2, Wenwen Mao3, Jin Liang1, Ling Yang2 1Department of Hematology, Yunnan Tumor Hospital, Kunming 650118, Yunnan, P. R. China; 2Department of He- matology, The Second Affiliated Hospital of Kunming Medical University, Kunming 650031, Yunnan, P. R. China; 3Department of Geriatric, Kunming 2nd People’s Hospital, Kunming 650204, Yunnan, P. R. China Received November 9, 2015; Accepted January 23, 2016; Epub June 15, 2016; Published June 30, 2016 Abstract: Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired hematopoietic stem cell clone disorder, and it is difficult to identify the difference between the untypical case of PNH and myelodysplastic syndrome (MDS). In current study, we described a case of PNH patient initially diagnosed as MDS and accepted treatment for 8 years, while lagging pathological symptoms of CD55/CD59 deficiency and soy urine was detected, the patient was eventu- ally confirmed the diagnosis of PNH. After received treatment of blood transfusion, corticosteroid injection, as well as basification of urine, the disease progression of the patient was suppressed which manifested with soy urine turn to clear and white blood cell (WBC), hemoglobin (Hb) as well as platelet (Plt) recovered completely. This case shows that untypical PNH tend to be easily misdiagnosed as MDS. Furthermore, it points out the potential effective methods of differentiation and diagnosis of PNH and MDS. Keywords: Paroxysmal nocturnal hemoglobinuria, myelodysplastic syndrome, CD55/CD59 deficiency, soy urine Introduction ria in 2011. In September 2003, he began to feel fatigue, heart palpitations, no fever, and Paroxysmal nocturnal hemoglobinuria (PNH) is bleeding gums without incentive. His initial an acquired nonmalignant stem cell clone dis- peripheral blood examination showed white order that results in partial or complete defi- blood cell (WBC), 2.3×109/L; hemoglobin (Hb), ciency of glycosylphosphatidylinositol (GPI)- 81 g/L and platelet (Plt), 25×109/L. The bone anchored membrane proteins, such as CD55 marrow puncture revealed that hyperplasia and CD59 [1]. Chronic intravascular hemolysis, was obviously active; the ratio of granulocyte to hematopoiesis failure and venous thrombosis erythrocytic (G:E) was 0.38:1, 0.5% of the are the clinical hallmarks of PNH [2]. It offers a nucleated marrow cells were myeloblasts, and challenge to differentiate PNH from other dis- megaloblastic change appears in bone marrow. orders, especially from myelodysplastic syn- These results suggested abnormal hematop- drome (MDS), for the correlative symptoms oiesis in granulocyte series, erythron series such as dyshematopoiesis and karyotypic ab- and megakaryocytic series in different extents. normalities of bone marrow (BM) cells [3, 4]. Meanwhile, the karyotypes of cells in BM were Here, we first report a case of a patient initially normal. The ratio of CD34+ cells to BM cells diagnosed with MDS and was confirmed as was 0.5% according to immunophenotyping cl- PNH 8 years later, which owe to the lagging soy assification, and no sign of vice infection were urine and deficiency of CD55/CD59, and we detected. Virological examination showed rela- also present a review of literature. tively normal levels of tumor markers CD55 and Case report CD59. Thus, the patient was preliminarily diag- nosed as MDS. In 2004, bone marrow puncture A 45-year-old male patient was admitted to our revealed marrow blast ratio 12%, tri-system hospital for 8-year MDS and 6-month hematu- dyshaematopoiesis, of peripheral blood cells, A case from PNH misdiagnosed as MDS for 8 years Table 1. Values of CD55/CD59 of patient and mography-computer tomography (PET-CT) normal individual in erythrocyte and neutro- scanning was normal. Flow cytometry analysis phil of peripheral blood cells indicated abnormal Index Patient Control expression of CD55 and CD59 in erythrocyte and neutrophil: CD55 (80.5%) and CD59 CD55 (Erythrocyte) 80.50% 95%-100% (41.7%) in erythrocyte were significantly lower CD59 (Erythrocyte) 41.70% 95%-100% than normal value; CD55 (7.2%) and CD59 CD55 (Neutrophil) 7.20% < 5% (34.2%) in neutrophil were obviously higher CD59 (Neutrophil) 34.20% < 5% than normal value (Table 1). Control: Normal individual. Combined with above mentioned check, he was clinically diagnosed with PNH. The treat- as well as normal karyotypes, which perform- ment regimen was including dexamethasone ed in Institute of Hematology, Tianjin, China. 15 mg, blood transfusion with washed red Therefore, the patient was suspected as MDS blood cells, Sodium bicarbonate for alkalinizing with International Prognostic Scoring System urine, plasmapheresis (plasma exchange) and (IPSS) score 2.0 and classified to intermedi- so on. Two weeks later, the patient left hospital ate-2 risk group. In April 2005, the marrow with the result of clear urine and normal value blast ratio in BM increased to 19% accompa- of blood consents (WBC, Hb, Plt). After more nied with pancytopenia and normal chromo- than one year (in June 2012), his WBC and Plt some, which were detected in Shanghai Sixth in peripheral blood were normal, while Hb was People’s Hospital. Thus, this patient was con- 85 g/L, lower than normal value. Moreover, this sidered as MDS refractory cytopenia with multi- was accompanied with intermittent soy urine. lineage dysplasia (MDS-RCMD) (IPSS2.0, inter- His follow-up is still ongoing. mediate-2 risk group). Because of the practi- cal difficulties, he only received symptomatic Discussion treatments. It is obvious that the case was initially with dys- In March 2011, this patient was hospitalized haematopoiesis, but without typical soy urine. for appearing typical paroxysmal soy urine, That is why he was misdiagnosed or missed accompanied with jaundice in period and pall- altogether. or anemia. Physical examination showed body temperature of 36.8°C, moderate anaemia in One intriguing thing is the blast cells in BM. In appearance, significant jaundice of the sclera, the course of disease the blast cells ratio was no skin hemorrhagic spot, as well as no abnor- from 0.5% to 19%, especially in the latter, the malities of heart, lung, liver or spleen. Blood diagnosis of MDS must be differentiate. To our examination revealed WBC count of 5.58× knowledge, the blast cells in PNH are still 109/L, Hb count of 65 g/L and Plt count of unclear now. Mannelli F et al. investigated sys- 25×109/L. The bone marrow puncture showed tematically the phenotypic proliferation of BM that nucleated cell hyperplasia was active; the cells from patients with PNH and MDS, and ratio of G: E was up to 0.6:1; granulocyte blood found the total amount of CD34+ cells on glob- cell ratio decreased, along with dikaryon and al cellularity were reduced, while antigenic pro- giant leaf nuclei granulocytes; while red cell liferation of CD34+ cells did not show relevant count was increased, with the appearances of abnormalities [5]. The data was parallel with megaloblastic erythroid-like change, double- the lack of significant differences of gene nucleated red blood cells, nuclear budding, expression and proliferation between CD34+ and other abnormal nuclear morphology as cells from PNH patients and healthy individuals well as active megakaryocyte series hyperpla- described by Chen G et al. [6]. It is important to sia; marrow iron-stain was positive; hemo- note that not even an abnormal karyotype can coagulation was normal, accompanied by a rule out a diagnosis of PNH, since abnormali- negative Coomb’s test. Biochemistry examina- ties have been reported in up to 24% of patients tion showed that total bilirubin, direct bilirubin [7]. So cytogenetic analyses, Chromosomes and indirect bilirubin were slight increased. and immune phenotype were performed from Lactic dehydrogenase (2072 U/L) was dramati- bone marrow in our case, no abnormalities cally higher than normal value (15-220 U/L). were found along with the clinical feature that Moreover, the result of positron emission to- the blast cells dropped to normal with condition 9626 Int J Clin Exp Med 2016;9(6):9625-9627 A case from PNH misdiagnosed as MDS for 8 years improved, an assumption was presented firstly [3] Brodsky RA. Advances in the diagnosis and that the increased blast cells of bone marrow in therapy of paroxysmal nocturnal hemoglobin- PNH might be a compensatory reaction to uria. Blood Rev 2008; 22: 65-74. reduce of cells in peripheral blood, which may [4] Araten DJ, Swirsky D, Karadimitris A, Notaro R, be the key reason of this case had been in PNH Nafa K, Bessler M, Thaler HT, Castro-Malaspi- na H, Childs BH, Boulad F, Weiss M, Anagnost- for ten years. Further studies addressing this opoulos N, Kutlar A, Savage DG, Maziarz RT, issue are warranted. Jhanwar S and Luzzatto L. Cytogenetic and morphological abnormalities in paroxysmal The other interesting finding is the expression nocturnal haemoglobinuria. Br J Haematol of CD 55 and CD59 in PNH. Although determi- 2001; 115: 360-368. nation of CD55 and CD59 in erythrocyte and [5] Mannelli F, Bencini S, Peruzzi B, Cutini I, Sanna neutrophil can be considered as a direct spe- A, Benelli M, Magi A, Gianfaldoni G, Rotunno G, cific and reliable method for the diagnosis of Carrai V, Gelli AM, Valle V, Santini V, Notaro R, PNH, PNH clones can be detected in the setting Luzzatto L and Bosi A. A systematic analysis of of MDS. PNH clone cells appeared in the high- bone marrow cells by flow cytometry defines a risk group of MDS patients, such as RAEB, specific phenotypic profile beyond GPI deficien- RAEB-t and CMML [8], While CD55/CD59 ex- cy in paroxysmal nocturnal hemoglobinuria. pression-lower cells were only in patients with Cytometry B Clin Cytom 2013; 84: 71-81.
Load more

Recommended publications
  • Unintentional Platelet Removal by Plasmapheresis
    Journal of Clinical Apheresis 16:55–60 (2001) Unintentional Platelet Removal by Plasmapheresis Jedidiah J. Perdue,1 Linda K. Chandler,2 Sara K. Vesely,1 Deanna S. Duvall,2 Ronald O. Gilcher,2 James W. Smith,2 and James N. George1* 1Hematology-Oncology Section, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 2Oklahoma Blood Institute, Oklahoma City, Oklahoma Therapeutic plasmapheresis may remove platelets as well as plasma. Unintentional platelet loss, if not recognized, may lead to inappropriate patient assessment and treatment. A patient with thrombotic thrombocytopenic purpura- hemolytic uremic syndrome (TTP-HUS) is reported in whom persistent thrombocytopenia was interpreted as continuing active disease; thrombocytopenia resolved only after plasma exchange treatments were stopped. This observation prompted a systematic study of platelet loss with plasmapheresis. Data are reported on platelet loss during 432 apheresis procedures in 71 patients with six disease categories using three different instruments. Com- paring the first procedure recorded for each patient, there was a significant difference among instrument types ,than with the COBE Spectra (1.6% (21 ס P<0.001); platelet loss was greater with the Fresenius AS 104 (17.5%, N) .With all procedures, platelet loss ranged from 0 to 71% .(24 ס or the Haemonetics LN9000 (2.6%, N (26 ס N Among disease categories, platelet loss was greater in patients with dysproteinemias who were treated for hyper- viscosity symptoms. Absolute platelet loss with the first recorded apheresis procedure, in the 34 patients who had a normal platelet count before the procedure, was also greater with the AS 104 (2.23 × 1011 platelets) than with the Spectra (0.29 × 1011 platelets) or the LN9000 (0.37 × 1011 platelets).
    [Show full text]
  • Platelet-Rich Plasmapheresis: a Meta-Analysis of Clinical Outcomes and Costs
    THE jOURNAL OF EXTRA-CORPOREAL TECHNOLOGY Original Article Platelet-Rich Plasmapheresis: A Meta-Analysis of Clinical Outcomes and Costs Chris Brown Mahoney , PhD Industrial Relations Center, Carlson School of Management, University of Minnesota, Minneapolis, MN Keywords: platelet-rich plasmapheresis, sequestration, cardiopulmonary bypass, outcomes, economics, meta-analysis Presented at the American Society of Extra-Corporeal Technology 35th International Conference, April 3-6, 1997, Phoenix, Arizona ABSTRACT Platelet-rich plasmapheresis (PRP) just prior to cardiopulmonary bypass (CPB) surgery is used to improve post CPB hemostasis and to minimize the risks associated with exposure to allogeneic blood and its components. Meta-analysis examines evidence ofPRP's impact on clinical outcomes by integrating the results across published research studies. Data on clinical outcomes was collected from 20 pub­ lished studies. These outcomes, DRG payment rates, and current national average costs were used to examine the impact of PRP on costs. This study provides evidence that the use of PRP results in improved clinical outcomes when compared to the identical control groups not receiving PRP. These improved clinical out­ comes result in subsequent lower costs per patient in the PRP groups. All clinical outcomes analyzed were improved: blood product usage, length of stay, intensive care stay, time to extu­ bation, incidence of cardiovascular accident, and incidence of reoperation. The most striking differences occur in use of all blood products, particularly packed red blood cells. This study provides an example of how initial expenditure on technology used during CPB results in overall cost savings. Estimated cost savings range from $2,505.00 to $4,209.00.
    [Show full text]
  • Management of Refractory Autoimmune Hemolytic Anemia Via Allogeneic Stem Cell Transplantation
    Bone Marrow Transplantation (2016) 51, 1504–1506 © 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved 0268-3369/16 www.nature.com/bmt LETTER TO THE EDITOR Management of refractory autoimmune hemolytic anemia via allogeneic stem cell transplantation Bone Marrow Transplantation (2016) 51, 1504–1506; doi:10.1038/ urine output and nausea. Physical examination was otherwise bmt.2016.152; published online 6 June 2016 normal. Her laboratory evaluation was notable for a hematocrit of 17%, reticulocyte count of 6.8%, haptoglobin below assay limits and an Waldenström’s macroglobulinemia (WM) represents a subset LDH (lactate dehydrogenase) that was not reportable due to of lymphoplasmacytic lymphomas in which clonally related hemolysis (Table 1). Creatinine was 1.1 mg/dL, total bilirubin was lymphoplasmacytic cells secrete a monoclonal IgM Ab.1 6.7 mg/dL with a direct bilirubin of 0.3 mg/dL and lactate was Overproduced IgMs can act as cold agglutinins in WM. Upon 5 mmol/L. Over 4 h, her hematocrit decreased to 6% and her exposure to cooler temperatures in the periphery, they cause creatinine rose to 1.6 mg/dL. Given concern for acute hemolytic anemia via binding to the erythrocyte Ii-antigen group and anemia due to cold agglutinins, she was warmed and received classical complement cascade initiation.2 Treatment of seven units of warmed, packed RBC, broad-spectrum antibiotics, cold-agglutinin-mediated autoimmune hemolytic anemia (AIHA) high-dose steroids and underwent emergent plasmapheresis. She in WM typically targets the pathogenic B-cell clone1–4 or the also underwent hemodialysis for presumed pigment nephropathy.
    [Show full text]
  • Patient Information Leaflet – Plasma Exchange Procedure
    Therapeutic Apheresis Services Patient Information Leaflet – Plasma Exchange Procedure Introduction Antibodies, which normally help to protect you from infection, can begin to attack your own This leaflet has been written to give patients healthy cells, or an over production of proteins can information about plasma exchange (sometimes cause your blood to become thicker and slow down called plasmapheresis). If you would like any more the blood flow throughout your body. A plasma information or have any questions, please ask the exchange can help improve your symptoms, doctors and nurses involved in your treatment at although this may not happen immediately. the NHS Blood and Transplant (NHSBT) Therapeutic Apheresis Services Unit. Although plasma exchange may help with symptoms, it will not normally cure your condition When you have considered the information given as it does not switch off the production of the in this leaflet, and after we have discussed the harmful antibodies or proteins. It is likely that procedure and its possible risks with you, we will this procedure will form only one part of your ask you to sign a consent form to indicate that you treatment. are happy for the procedure to go ahead. Before any further procedures we will again check that you are happy to proceed. How do we perform Plasma Exchange? What is a plasma exchange? Plasma exchange is performed using a machine Blood is made up of red cells, white cells and called a Blood Cell Separator which can separate platelets which are carried around in fluid called blood into its various parts. The machine separates plasma.
    [Show full text]
  • Recommendations for Collecting Red Blood Cells by Automated Apheresis Methods
    Guidance for Industry Recommendations for Collecting Red Blood Cells by Automated Apheresis Methods Additional copies of this guidance document are available from: Office of Communication, Training and Manufacturers Assistance (HFM-40) 1401 Rockville Pike, Rockville, MD 20852-1448 (Tel) 1-800-835-4709 or 301-827-1800 (Internet) http://www.fda.gov/cber/guidelines.htm U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research (CBER) January 2001 Technical Correction February 2001 TABLE OF CONTENTS Note: Page numbering may vary for documents distributed electronically. I. INTRODUCTION ............................................................................................................. 1 II. BACKGROUND................................................................................................................ 1 III. CHANGES FROM THE DRAFT GUIDANCE .............................................................. 2 IV. RECOMMENDED DONOR SELECTION CRITERIA FOR THE AUTOMATED RED BLOOD CELL COLLECTION PROTOCOLS ..................................................... 3 V. RECOMMENDED RED BLOOD CELL PRODUCT QUALITY CONTROL............ 5 VI. REGISTRATION AND LICENSING PROCEDURES FOR THE MANUFACTURE OF RED BLOOD CELLS COLLECTED BY AUTOMATED METHODS.................. 7 VII. ADDITIONAL REQUIREMENTS.................................................................................. 9 i GUIDANCE FOR INDUSTRY Recommendations for Collecting Red Blood Cells by Automated Apheresis Methods This
    [Show full text]
  • Utility of Double Filtration Plasmapheresis in Acute Antibody
    doi: 10.5262/tndt.2011.1003.17 Olgu Sunumu/Case Report Utility of Double Filtration Plasmapheresis in Acute Antibody Mediated Renal Allograft Rejection: Report of Three Cases Akut Antikor Aracılı Renal Allograt Rejeksiyonunda Çift Filtrasyon Plazmaferez: Üç Vaka Bildirimi ABSTRACT Yalçın SOLAK1 Hüseyin ATALAY1 Plasmapheresis is an extracorporeal procedure, which is often employed to rapidly lower circulating 2 titers of autoantibodies, immune complexes or toxins. There are two types of plasmapheresis namely, İlker POLAT 1 regular plasmapheresis (RPP) by centrifugation and membrane fi ltration, and double fi ltration Melih ANIL 1 plasmapheresis (DFPP) which is a special form of membrane fi ltration in which two membranes called Kültigin TÜRKMEN 1 as plasma separator and plasma fractionator are employed to fi lter macromolecules more selectively. Zeynep BIYIK 1 DFPP have several advantages over RP. Despite widespread utilization of DFPP in the setting of ABO Mehdi YEKSAN blood group incompatible kidney transplantation, there is no report regarding DFPP in patients with antibody mediated acute renal allograft rejection who are good candidates for benefi cial effects of DFPP. Here we report three renal transplant recipients in whom DFPP was applied as a component of anti-rejection treatment regimen. 1 Selcuk University Faculty of Medicine, KEYWORDS: Kidney, Transplantation, Rejection, Plasmapheresis Department of Nephrology, Konya, Turkey 2 Selcuk University Faculty of Medicine, ÖZ Department of Internal Medicine, Konya, Turkey Plazmaferez, dolaşımdaki antikor, immün kompleks ve toksin düzeylerini hızla düşürmek için kullanılan bir ekstrakorporeal yöntemdir.İki tip plazmaferez bulunmaktadır: Santrifüj ve membran fi ltrasyonu ile yapılan regüler plazmaferez (RP) ve büyük moleküllerin daha selektif olarak fi ltre edildiği, plazma ayırıcısı ve plazma fraksiyoneri olarak adlandırılan iki membranın kullanıldığı özel bir fi ltrasyon şekli olan çift fi ltrasyon plazmaferezdir (ÇFP).ÇFP’nin RP’ye göre bazı avantajları vardır.
    [Show full text]
  • Another Brick in the Wall: Serum Sickness
    Scholars Journal of Medical Case Reports ISSN 2347-6559 (Online) Sch J Med Case Rep 2017; 5(10):615-617 ISSN 2347-9507 (Print) ©Scholars Academic and Scientific Publishers (SAS Publishers) (An International Publisher for Academic and Scientific Resources) Does So Frequent Use Of It Make Innocent? Another Brick In The Wall: Serum Sickness Induced By Horse-Antithymocyte Globulin In A Patient With Bone Marrow Failure Gokhan Ozgur1, Adem Aydin2, Musa Baris Aykan3, Murat Yildirim4, Selim Sayin5, Cengiz Beyan6 1Gülhane Training and Research Hospital, Clinical of Hematology, Etlik, Ankara, Turkey 2Health Sciences University, Gulhane School of Medicine, Department of Internal Medicine, Etlik, Ankara, Turkey 3TOBB University of Economics and Technology Faculty of Medicine, Department of Internal Medicine, Çankaya, Ankara, Turkey Abstract: Aplastic anemia is a condition characterized by the absence or decrease *Corresponding author of hematopoietic progenitor cells in the bone marrow. The disease is considered to Adem Aydin occur as a result of immune response triggered by the environmental factors, infective agents or endogenous antigens. Cyclosporine and antithymocyte globulin Article History is recommended as first line therapy in patients have no unidentified suitable donor Received: 22.09.2017 or hematopoietic stem cell transplantation cannot be done. However, despite skin Accepted: 09.10.2017 testing for hypersensitivity and concomitant steroids, adverse effects are sometimes Published:30.10.2017 unavoidable. 30-year-old female patient, fallowed with aplastic anemia since 2012, was admitted to hospital with painful swelling in the neck, rash and joint pain DOI: began after ATG. Laboratory examination revealed pancytopenia, elevated 10.21276/sjmcr.2017.5.10.5 erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP).
    [Show full text]
  • Practice Guidelines for Perioperative Blood Management an Updated Report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management*
    PRACTICE PARAMETERS Practice Guidelines for Perioperative Blood Management An Updated Report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management* RACTICE guidelines are systematically developed rec- • What other guidelines are available on this topic? ommendations that assist the practitioner and patient in o These Practice Guidelines update “Practice Guidelines for P Perioperative Blood Transfusion and Adjuvant Therapies: An making decisions about health care. These recommendations Updated Report by the American Society of Anesthesiolo- may be adopted, modified, or rejected according to clinical gists Task Force on Perioperative Blood Transfusion and Ad- needs and constraints, and are not intended to replace local juvant Therapies” adopted by the American Society of Anes- thesiologists (ASA) in 2005 and published in 2006.1 institutional policies. In addition, practice guidelines devel- o Other guidelines on the topic for the management of blood oped by the American Society of Anesthesiologists (ASA) are transfusion have been published by the ASA, American College not intended as standards or absolute requirements, and their of Cardiology/American Heart Association,2 Society of Thoracic 3 use cannot guarantee any specific outcome. Practice guidelines Surgeons, Society of Cardiovascular Anesthesiologists, and the American Association of Blood Banks.4 The field of Blood Con- are subject to revision as warranted by the evolution of medi- servation has advanced considerably since the publication of the cal knowledge, technology, and practice. They provide basic ASA Guidelines for Transfusion and Adjuvant Therapies in ANES- recommendations that are supported by a synthesis and analy- THESIOLOGY in 2006. sis of the current literature, expert and practitioner opinion, • Why was this guideline developed? o In October 2012, the Committee on Standards and Practice open forum commentary, and clinical feasibility data.
    [Show full text]
  • Package Insert
    Individuals using assistive technology may not be able to fully access the information contained in this file. For assistance, please send an e-mail to: [email protected] and include 508 Accommodation and the title of the document in the subject line of your e-mail. HIGHLIGHTS OF PRESCRIBING INFORMATION • Severe deficiency of Protein S These highlights do not include all the information needed to use Octaplas • History of hypersensitivity to fresh frozen plasma (FFP) or to plasma- safely and effectively. See full prescribing information for Octaplas. derived products including any plasma protein • History of hypersensitivity reaction to Octaplas Octaplas, Pooled Plasma (Human), Solvent/Detergent Treated Solution for Intravenous Infusion -----------------------WARNINGS AND PRECAUTIONS------------------------ Initial U.S. Approval: 2013 • Transfusion reactions can occur with ABO blood group mismatch (5.1) • High infusion rates can induce hypervolemia with consequent ----------------------------INDICATIONS AND USAGE-------------------------- pulmonary edema or heart failure (5.2) Octaplas is a solvent/detergent (S/D) treated, pooled human plasma indicated • Excessive bleeding due to hyperfibrinolysis can occur due to low levels for of alpha 2-antiplasmin (5.3) • Replacement of multiple coagulation factors in patients with acquired • Thrombosis can occur due to low levels of Protein S (5.4) deficiencies • Citrate toxicity can occur with volumes exceeding one milliliter of due to liver disease o Octaplas per kg per minute (5.5) undergoing cardiac surgery or liver transplantation o • Octaplas is made from human blood and may carry the risk of • Plasma exchange in patients with thrombotic thrombocytopenic purpura transmitting infectious agents, e.g., viruses and theoretically, the variant (TTP) Creutzfeldt-Jakob disease and Creutzfeldt-Jakob disease agent (5.6) ----------------------DOSAGE AND ADMINISTRATION----------------------- For intravenous use only.
    [Show full text]
  • Procedure: Therapeutic Plasma Exchange (Also Referred to As Therapeutic Plasmapheresis)
    PROCEDURE: THERAPEUTIC PLASMA EXCHANGE (ALSO REFERRED TO AS THERAPEUTIC PLASMAPHERESIS) DESCRIPTION: Plasma refers to the “liquid” portion of the blood which contains proteins, electrolytes, vitamins, hormones, etc. It does not include the red blood cells, white blood cells or platelets. Plasma exchange is a procedure in which a machine separates and removes the patient’s plasma, replacing it with another fluid. The most commonly used fluid for replacement is 5% human albumin (a protein solution). In some cases plasma donated from other people is used. Many types of machines are available: the most common ones use a centrifuge to separate the blood into its different parts. To keep blood from clotting during the treatment, a solution containing citrate is used. REASON FOR THE PROCEDURE: RISKS AND SIDE EFFECTS: Plasma exchange is used when it is necessary to remove Plasma exchange is a safe procedure but side effects can oc- disease-causing proteins, called antibodies, from a patient. cur. Common side effects include fatigue, nausea, dizziness, These antibodies, found in the plasma, are caused by an ab- feeling cold and tingling in the fingers and around the mouth, normal immune system and can attack healthy organs. It is allergic reaction, and lowered blood pressure. It is very im- often not possible to remove only the protein that is causing portant to notify medical staff is these symptoms occur. Se- the disease. Therefore, the plasma must be removed to treat rious complications such as abnormal heart beat, seizures, the illness. electrolyte abnormalities, and unexplained bleeding are ex- tremely rare. VENOUS ACCESS: NUMBER OF PROCEDURES THAT ARE In some cases, plasma exchange can be done using needles that are placed in each arm.
    [Show full text]
  • Guidelines on the Use of Therapeutic Apheresis In
    DOI: 10.1002/jca.21705 Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue Anand Padmanabhan1 | Laura Connelly-Smith2 | Nicole Aqui3 | Rasheed A. Balogun4 | Reinhard Klingel5 | Erin Meyer6 | Huy P. Pham7 | Jennifer Schneiderman8 | Volker Witt9 | Yanyun Wu10 | Nicole D. Zantek11 | Nancy M. Dunbar12 | Guest Editor: Joseph Schwartz13 1Medical Sciences Institute & Blood Research Institute, Versiti & Department of Pathology, Medical College of Wisconsin, Milwaukee, Wisconsin 2Department of Medicine, Seattle Cancer Care Alliance & University of Washington, Seattle, Washington 3Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 4Department of Medicine, University of Virginia, Charlottesville, Virginia 5Apheresis Research Institute, Cologne, Germany & First Department of Internal Medicine, University of Mainz, Mainz, Germany 6Department of Hematology/Oncology/BMT/Pathology, Nationwide Children’s Hospital, Columbus, Ohio 7Department of Pathology, Keck School of Medicine of the University of Southern California, Los Angeles, California 8Department of Pediatric Hematology/Oncology/Neuro-oncology/Stem Cell Transplant, Ann & Robert H. Lurie Children’s Hospital of Chicago, Northwestern University, Chicago, Illinois 9Department for Pediatrics, St. Anna Kinderspital, Medical University of Vienna, Vienna, Austria 10Bloodworks NW & Department
    [Show full text]
  • Posttransplant Focal Segmental Glomerulosclerosis Recurrence
    doi: 10.5262/tndt.2015.1001.06 Özgün Araştırma/Original Investigation An Important Problem: Posttransplant Focal Segmental Glomerulosclerosis Recurrence and Plasmapheresis Önemli Bir Problem: Transplantasyon Sonrası Fokal Segmental Glomeruloskleroz Nüksü ve Plazmaferez ABSTRACT Türker EMRE1 Rümeyza KAzAncIOğlu2 OBJecTIve: Focal segmental glomerulosclerosis (FSGS) as a primary glomerular disease are 3 refractory to therapy and progress to End stage renal disease. (ESRD). After transplantation, the major Hüseyin DOğAn 4 problems are recurrence of the disease and its treatment. In this study, We investigated FSGS recurrence. Yaşar Kerem ÇAlIşKAn Serdar KAHveciOğlu5 MATeRIAl and MeTHODS: The graft and patient’s survivals, complications, recurrence rates, and Aydın TÜRKMEN4 therapeutic approach were documented. Twenty patients with FSGS and 20 patients as controls were included in the study. ReSulTS: The recurrence rate was significantly higher in FSGS group than controls (55 % vs 0 %, p<0.0001). We found that living and cadaveric donor transplantation have similar survival rate in FSGS. One of the most effecting factors on graft survival was genetic similarities between recipient and 1 İstanbul Research and Training donor. Pre transplant plasmapheresis was found as effective treatment way for the prevention of FSGS Hospital, Department of Nephrology, recurrence. While proteinuria recurrence was 38% in the preemptive plasmapheresis group, it was 85% İstanbul, Turkey in the other patients with FSGS (p<0.05). 2 Bezmialem Vakıf Universty, Faculty of Medicine, Department of Nephrology, cOncluSIOn: The importance of genetic similarities, similar results for graft survival in both living İstanbul, Turkey and cadaveric donor transplantation, and plasmapheresis as an effective approach for recurrent disease 3 Fatih Private Dialysis Center, were the most important findings in this study.
    [Show full text]